# A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC

> **NCT04990258** · — · UNKNOWN · sponsor: **Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives** · enrollment: 444 (actual)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Subcutaneous infliximab CT-P13 Remsima®SC

## Key facts

- **NCT ID:** NCT04990258
- **Lead sponsor:** Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-06
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 444 (ACTUAL)
- **Last updated:** 2024-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04990258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04990258, "A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04990258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*